A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

Valneva SE (VALN) said that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to ...

Kepler Capital analyst Justine Telliez maintained a Buy rating on Valneva (0OB3 – Research Report) on September 18 and set a price ...

Valneva SE (NASDAQ:VALN) and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 ...

Nearly half a million Americans received an unpleasant surprise this summer, according to insurance billing data: a new ...

Valneva and Pfizer have reported positive data from a Phase II trial of a second booster dose of their Lyme disease vaccine ...

The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.

Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to ...

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. The French ...

Valneva said it expects to submit data to the U.S. Food and Drug Administration (FDA) this year to also support potential label extensions in the U.S. The vaccine is currently approved in the U.S ...

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine ...

Valneva is seeking label extensions in Europe and Canada for the world’s only licensed chikungunya vaccine, Ixchiq, to be used in adolescents, with further plans to file for US approval.